menu
    • menu
    [{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Ophthalmology Pharmaceutical","pharmaFlowCategory":"D","amount":"Undisclosed","upfrontCash":"Undisclosed","newsHeadline":"Ophthalmology Pharmaceutical and IACTA Pharmaceuticals Sign New Licensing Agreement for Dry Eye Treatment","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Phase II","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"July 2020","year":"2020","type":"Licensing Agreement","leadProduct":"IC 265","moa":"SYK","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Phase II","graph3":"IACTA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Phase II","highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"","sponsorNew":"IACTA Pharmaceuticals \/ Ophthalmology Pharmaceutical","highestDevelopmentStatusID":"8","companyTruncated":"IACTA Phar.."},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"Pharmaleads","pharmaFlowCategory":"D","amount":"$100.0 million","upfrontCash":"Undisclosed","newsHeadline":"IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"IND Enabling","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"January 2021","year":"2021","type":"Collaboration","leadProduct":"IC 800","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"IACTA Pharmaceuticals","amount2":0.10000000000000001,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"IND Enabling","highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0.10000000000000001,"dosageForm":"","sponsorNew":"IACTA Pharmaceuticals \/ IACTA","highestDevelopmentStatusID":"5","companyTruncated":"IACTA Phar.."},{"orgOrder":0,"company":"IACTA Pharmaceuticals","sponsor":"U.S. Army Medical Research Acquisition Activity","pharmaFlowCategory":"D","amount":"$1.0 million","upfrontCash":"Undisclosed","newsHeadline":"IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclinical Studies of IC 800 to Treat Pain Relief for Eye Injury","therapeuticArea":"Ophthalmology","highestDevelopmentStatus":"Preclinical","country":"","productType":"Undisclosed","productStatus":"New Molecular Entity","date":"October 2021","year":"2021","type":"Funding","leadProduct":"IC 800","moa":"","url1":"","url2":"","graph1":"Ophthalmology","graph2":"Preclinical","graph3":"IACTA Pharmaceuticals","amount2":0,"therapeuticAreaNew":"Ophthalmology","highestDevelopmentStatusNew":"Preclinical","highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Ophthalmology","productSubType":"","amount2New":0,"dosageForm":"Topical","sponsorNew":"IACTA Pharmaceuticals \/ U.S. Army Medical Research Acquisition Activity","highestDevelopmentStatusID":"4","companyTruncated":"IACTA Phar.."}]

    Find Clinical Drug Pipeline Developments & Deals by IACTA Pharmaceuticals

    Menu

    IACTA Pharmaceuticals

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            IACTA Pharmaceuticals

                            Puerto Rico arrow
                            BioProcess International
                            Not Confirmed

                            IACTA Pharmaceuticals

                            Puerto Rico arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 800

                            Therapeutic Area : Ophthalmology

                            Study Phase : Preclinical

                            Sponsor : U.S. Army Medical Research Acquisition Activity

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            DEALS_DEV arrow-down

                            IACTA Pharmaceuticals Receives U.S. Department of Defense Funding of $1 Million to Conduct Preclin...

                            Details : The award will be used for the development and preclinical studies of IC 800, a novel therapy for the topical treatment of ocular pain, utilizing the body’s endogenous pain controllers, the enkephalins.

                            Brand Name : IC 800

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            October 28, 2021

                            Lead Product(s) : IC 800

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Preclinical

                            Sponsor : U.S. Army Medical Research Acquisition Activity

                            Deal Size : $1.0 million

                            Deal Type : Funding

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            IACTA Pharmaceuticals

                            Puerto Rico arrow
                            BioProcess International
                            Not Confirmed

                            IACTA Pharmaceuticals

                            Puerto Rico arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 800

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Recipient : Pharmaleads

                            Deal Size : $100.0 million

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            IACTA Pharmaceuticals and Pharmaleads to Develop the World's First Epithelial Protective Drug

                            Details : Under the terms of these agreements, Pharmaleads and Pharmaleads Greater China have granted IACTA an exclusive, worldwide, royalty-bearing license to lead the clinical and commercial development of IC800 ...

                            Brand Name : IC 800

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            January 07, 2021

                            Lead Product(s) : IC 800

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Recipient : Pharmaleads

                            Deal Size : $100.0 million

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            IACTA Pharmaceuticals

                            Puerto Rico arrow
                            BioProcess International
                            Not Confirmed

                            IACTA Pharmaceuticals

                            Puerto Rico arrow
                            BioProcess International
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : IC 265

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase II

                            Sponsor : Ophthalmology Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Ophthalmology Pharmaceutical and IACTA Pharmaceuticals Sign New Licensing Agreement for Dry Eye Tr...

                            Details : The exclusive license is for ophthalmic indications in China and other countries of Southeast Asia. The agreement will accelerate the development of IC 265 and IC 270 in both China and the U.S.

                            Brand Name : IC 265

                            Molecule Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 28, 2020

                            Lead Product(s) : IC 265

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase II

                            Sponsor : Ophthalmology Pharmaceutical

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth